Board Appointment

Oxford Biomedica PLC
10 March 2008



FOR IMMEDIATE RELEASE                                           10 MARCH 2008



       OXFORD BIOMEDICA APPOINTS DR ALEX LEWIS AS NON-EXECUTIVE DIRECTOR

Oxford, UK - 10 March 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announced today that Dr Alexander D Lewis will join the Board on 3
April 2008 as a Non-executive Director and member of the Remuneration and Audit
Committees.

Dr Lewis is an experienced consultant to the pharmaceutical and biotech industry
with a background of over 20 years in medical research and drug development.
Until 1 January 2008, Dr Lewis was head of the Partnering and Due Diligence
Practice at leading consultants Wood Mackenzie and was based in their Boston
office. Dr Lewis' assignments have involved supporting investment banks with
their corporate finance activities, including selection of acquisition targets,
due diligence, expert reports and listing particulars; as well as advising
pharmaceutical and biotech clients with their licensing strategy for in and out
licensing and asset identification, general corporate strategy in terms of
research and development and also mergers and acquisitions; and also performing
due diligence on companies, products and technologies. Dr Lewis has also been
involved in the provision of the expert reports and technical advice for Initial
Public Offerings (IPO's) and fundraising activities of biotech companies based
in the USA and Europe.

Professor Alan Kingsman, Chief Executive Officer of Oxford BioMedica, said: 'We
are delighted that Alex has agreed to join the board of Oxford BioMedica. His
exceptional experience and broad-based knowledge will complement the existing
team and help take the Company forward through its next exciting stages of
commercial and operational development.'

There is no other information to be disclosed under Paragraph 9.6.13 R of the
Listing Rules.


-Ends-

For further information, please contact:
Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive            Tel: [phone]
JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson                          Tel: [phone]
City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson        Tel: [phone]
Buchanan Communications
Scientific/Trade Press Enquiries:

Gemma Price/ Holly Griffiths/ Katja Stout           Tel: [phone]

College Hill Life Sciences
US Enquiries:

Thomas Fechtner                                          Tel: [phone]

The Trout Group LLC


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in
cancer immunotherapy and gene-based therapies. The Company was established in
1995, as a spin-out from Oxford University, and is listed on the London Stock
Exchange.


The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. The lead product candidate is TroVax(R),
an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis
for global development and commercialisation. TroVax is in Phase III
development. Oxford BioMedica has three other products in clinical development,
including ProSavin(R), a novel gene-based treatment for Parkinson's disease, in
a Phase I/II trial. The Company is underpinned by over 80 patent families, which
represent one of the broadest patent estates in the field. The Company has a
staff of approximately 85. Oxford BioMedica has collaborations with
sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees
include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange